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Abstract
Background: MHC class I-restricted CD8+ cytotoxic T lymphocytes (CTL) are thought to play a
major role in clearing virus and promoting recovery from influenza infection and disease. This has
been demonstrated for clearance of influenza virus from the lungs of infected mice. However,
human influenza infection is primarily a respiratory mucosal infection involving the nasopharynx and
tracheobronchial tree. The role of CD8+ CTL directed toward the influenza nucleoprotein (NP) in
defense against influenza virus infection at the respiratory mucosa was evaluated in two separate
adoptive transfer experiments.
Methods: Influenza nucleoprotein (NP)-specific CD8+ CTL were generated from splenocytes
obtained from Balb/c mice previously primed with influenza A/Taiwan/1/86 (H1N1) infection or
with influenza A/PR/8/34 (H1N1)-derived NP plasmid DNA vaccine followed by infection with A/
Hong Kong/68 (H3N2) virus. After in vitro expansion by exposure to an influenza NP-vaccinia
recombinant, highly purified CD8+ T cells exhibited significant lysis in vitro of P815 target cells
infected with A/Hong Kong/68 (H3N2) virus while the CD8- fraction (CD4+ T cells, B cells and
macrophages) had no CTL activity. Purified CD8+ and CD8- T cells (1 × 107) were injected
intravenously or interperitoneally into naive mice four hours prior to intranasal challenge with A/
HK/68 (H3N2) virus.
Results: The adoptively transferred NP-vaccinia-induced CD8+ T cells caused significant reduction
of virus titers in both the lungs and nasal passages when compared to CD8- cells. Neither CD8+
nor CD8- T cells from cultures stimulated with HIV gp120-vaccinia recombinant reduced virus
titers.
Conclusion: The present data demonstrate that influenza NP-specific CD8+ CTL can play a direct
role in clearance of influenza virus from the upper respiratory mucosal surfaces.
Background
Studies in mice have shown definitively that MHC class I-
restricted CD8+ CTL can promote recovery from pneumo-
nia caused by an influenza virus infection [1,2]. Proof was
provided using adoptive transfer of CD8+  T cells and
clones [3,4,1], in vivo depletion of CD8+ T cells using mon-
oclonal antibodies from mice previously infected with
influenza virus [5,6] and transgenic CD8+ T cell knockout
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mice [7]. CD8+ CTL mediated clearance of lung virus
infection, reduced pneumonia severity and prevented
mortality from the influenza virus infection.
Despite availability of data for mice, a beneficial role for
CTL activity in promoting clearance of influenza virus
infection in human influenza cannot be assumed because
influenza in humans is primarily an infection of the
mucosal surface of the respiratory tract; pneumonia can
occur but this is uncommon [8]. Thus, for CTLs to be of
value for human influenza, they must mediate control of
virus infection of respiratory tract epithelial cells. In this
regard, it has been suggested that CTLs in the circulation
or submucosal sites cannot cross the basement membrane
of the mucosal surface; this should be necessary to exert
an effect [9]. Studies by McMichael and coworkers dem-
onstrated a correlation between human HLA-restricted
CTL activity and reduced viral shedding from the
nasopharynx of humans; however a contribution from
antibody could not be excluded [10].
CD8+ CTL for influenza virus infection are directed pre-
dominantly toward antigens on the nucleoprotein (NP)
[11-14]. Antibody to NP has clearly been shown to have
no role in prevention or recovery from infection [15,16]
so a beneficial immune response directed specifically
toward the NP would be a cell mediated immune
response; antibodies that could contribute to the control
of influenza are directed toward the hemagglutinin and
neuraminidase surface proteins [15] or the M2 protein
[17]. The objective of the present study was to define the
role of CD8+  CTL directed toward the NP protein in
defense against influenza virus infection of the respiratory
mucosa.
Methods
Mice
Eight- to twelve- week old Balb/c (H-2d) mice were pur-
chased from Charles River Laboratories under a contrac-
tual arrangement with the National Institute on Aging and
were housed in specific pathogen-free-certified rooms in
cages covered with barrier filters and with sentinel cages to
monitor infections.
Influenza viruses
Virulent challenge pools of mouse-adapted influenza
viruses A/Hong Kong/1/68 (A/H3N2) and A/Taiwan/1/86
(A/H1N1) viruses were prepared by serially passaging
each virus in mice as described previously [18-20]. The NP
of A/HK/68 and A/Taiwan/1/86 viruses are antigenically
similar to each other and to A/PR/8/34 (H1N1) virus NP
while the HA and NA surface glycoproteins of A/HK/68
and A/Taiwan/86 are antigenically distinct. A mouse fifty
percent lethal dose (MID50) following administration by
small particle aerosol (SPA) was determined for each virus
as described previously [18-20]. A mouse fifty percent
infectious dose (MID50) was determined following intra-
nasal (i.n.) administration of a small volume (10 μl) of
virus suspension. Viruses for use in CTL assays were pre-
pared as described previously by us [18-20].
DNA vaccine
An influenza NP plasmid DNA vaccine was obtained from
Drs. Margaret Liu and Donna Montgomery of Merck
Research Laboratories, West Pont, PA [21,22]. The expres-
sion vector system (VIJ) consists of a pUC19 backbone
with an IE1 enhancer promoter intron A of hCMV
(CMVintA) and a bovine growth hormone (BGH) polya-
denylation (poly A) signal sequence for driving the
expression of the reporter gene chloramphenicol acetyl-
transferase (CAT) or the influenza protein [21]. The NP
gene from influenza A/PR/8/34 was cloned into the BglII
and SalI sites. Plasmid DNA used for vaccination was puri-
fied from E. coli (DH5a) containing VIJ-NP by a modified
alkaline lysis procedure using QIAGEN (Chatsworth, CA)
Giga Plasmid Purification kits. The DNA was banded
twice on CsCl2 gradients.
Vaccinia viral gene recombinants
Thymidine kinase-negative (TK-) recombinant vaccinia
virus expressing influenza A/PR/8/34 NP gene (NP-Vac)
was provided by Dr. Bernard Moss, NIH, Bethesda, MD
[23]. Vaccinia recombinant expressing HIV gp120 (Vac-
gp120) [24,25] was obtained from the AIDS Research and
Reference Reagents Program, Division of AIDS, NIAID,
NIH.
Immunizations
Mice were infected with live virus by administering 0.05
LD50  A/Taiwan/86 by small particle aerosolization
[19,18,20]. For DNA vaccination, mice were anesthetized
by subcutaneous injection of 25 μl of ketamine-xylazine-
acepromazine cocktail (37.5/1.9/0.37 mg/ml). The legs of
the mice were then flooded with 70% ethanol and NP
DNA (200 μg) was injected into each anterior tibial mus-
cle 3 times, 2 weeks apart. Three weeks after the last dose,
DNA-immunized mice were challenged with 1 LD50 of A/
HK/68 (H3N2) virus by small particle aerosol. Sixty to
eighty percent of the mice survived.
Generation of secondary CTL activity and chromium 
release assay for CTL
Spleen cells were obtained from mice immunized with A/
Taiwan/86 and from DNA-immunized mice surviving A/
HK/68 virus challenge (after 3–4 months). Influenza
virus-specific and NP-specific CTL were generated as pre-
viously described [20,26]. Briefly, stimulator cells were
prepared by infecting spleen cells with A/HK/68 (H3N2)
virus and washing. In addition, cells were infected with 1
pfu of Vac-NP or Vac-gp120 for 2 hours and irradiatedRespiratory Research 2007, 8:44 http://respiratory-research.com/content/8/1/44
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using a cesium source (2500 rads). The stimulators were
then co-cultured with responder cells at a 1:10 ratio for 5
days. CTL effectors were harvested, depleted of dead cells
using Ficoll Hypaque gradient centrifugation. Tests for
CTL activity against A/HK/68-infected P815 (H-2d) target
cells was assessed in a 4-hour 51Cr release assay [20,26].
Purification of CD8+ T cells
CD8+ T cells were purified by negative selection using the
magnetic affinity cell sorting MACS method [20,26,27].
Alternatively cells were purified by positive selection using
AutoMacs mini cell sorter (Miltenyi Biotec, Auburn, CA).
Briefly, effector cells (107) were incubated with 20 μl of
magnetic CD8a (Ly-2) MicroBeads™ (Miltenyi Biotec;
MicroBeads conjugated to rat monoclonal anti-mouse
CD8a Ly-2 antibody) for 30 minutes at 4°C and washed.
After passing through a column placed in the magnetic
field of an AutoMacs, purified CD8+ T cells and CD8- cells
(CD4+ T cells, B cells and macrophages) were eluted. The
frequency of CD8+ and CD4+ cells in each fraction was
determined using PE-conjugated rat anti-mouse CD8a
(Ly-2) (clone 53-6.7) and FITC-conjugated Rat Anti-
Mouse CD4 (L3T4), IgG2b, clone GK1.5, BD Biosciences)
by dual color flow cytometry (Beckman Coulter, Miami,
FL). The AutoMacs positive selection is more sensitive
than the MACS technique, but the purity of target cells are
similar.
Adoptive transfer of T lymphocytes and virus challenge
Purified CD8+ T cells and CD8- cells were suspended in
PBS at 1 × 107 cells/ml. Using a 27 gauge needle, naïve
mice were injected in the tail vein or intraperitoneally
with a 0.1 ml volume to deliver 1 × 107 cells. Four hours
later, they were challenged by intranasal inoculation with
10 μl containing 100–200 MID50 of A/HK/68 (H3N2)
virus. Lung and nasopharyngeal virus titers were assessed
8 days later.
Quantitation of lung and nasopharyngeal virus
Lungs from infected mice were obtained aseptically at dif-
ferent times following virus challenge and homogenized
in vials containing 1 μm glass beads using a Mini-bead
beater (Biospec Products, Bartlesville, OK) as previously
described [26-28]. For nose washes, jaws of the dead ani-
mals were disarticulated and then removed. One ml of 2%
FCS-MEM was pushed through each nostril and the efflu-
ent collected from the posterior opening of the pallet.
Nasal turbinates were also isolated and homogenized as
for lungs. Lung, nasal wash and turbinate specimens were
titrated for influenza virus in microplates of MDCK tissue
cultures [29,28,26].
Data analysis
The Mann Whitney nonparametric analysis was used to
compare geometric mean titers in different groups. Lung
and nasal turbinate homogenates and nose wash samples
with undetectable virus titers (< 1 TCID50) were assigned
a value of 0.7 TCID10 for statistical evaluation. These tests
were performed using STATVIEW Software (SAS Institute,
Inc, Cary, NC). A difference between comparison groups
of p < 0.05 level was considered significant.
Results
Characterization of purified CD8+ T cells
CTL effector cells were depleted of dead cells and then
labeled with anti-CD8 MicroBeads and isolated using the
AutoMacs cell sorter (Miltenyi Biotec); cell recovery is usu-
ally low (< 50%). The purity of CD8+ T cells was deter-
mined using dual color (anti-CD4-FITC and anti-CD8-
PE) flow cytometry; Figure 1 shows the results of a typical
phenotypic analysis. Prior to separation, 13.4% of the
effector cells were CD8+ while 70.3% were CD4+; after
purification, greater than 98% of the cells were CD8+ T
cells while CD4+ cells were undetectable.
Table 1 shows the frequency of CD8+ and CD4+ T cells and
the corresponding influenza-specific CTL activity in the
CD8- and CD8+ fractions after positive isolation of CD8+ T
cells in a typical experiment. Following 5 days of in vitro
stimulation with vaccinia-NP, the CD8+ cells exhibited
significant lysis of P815 (H-2d) target cells infected with
influenza A/HK/68 (H3N2) and vaccinia-NP but failed to
lyse vaccinia-gp120- and B/Panama influenza-infected
target cells. While similar cell frequencies were used for
vaccinia-gp120-stimulated cells, the CD8+ T cells did not
display significant lysis of influenza A/HK/68 virus, vac-
cinia-NP- infected or vaccinia-gp120-infected target cells.
The CD8- fractions also failed to exhibit appreciable lysis
of any of the target cells. Influenza A/HK/68-infected EL-
4 (H-2b) target cells were not lysed by NP-specific CD8+ T
cells (data not shown). These results confirm influenza A
virus specificity and MHC class I restriction of the cells
used for adoptive immunizations.
Protective effects of NP-specific CD8+ 
i) T cells from influenza infected mice
Previous studies have shown that influenza-induced
CD8+ T cells reduced pulmonary influenza infection fol-
lowing adoptive transfer. To confirm this and to evaluate
the protective effect of CD8+ T cells at the upper respira-
tory mucosal site in the same mice, Balb/c mice were
infected with 0.05LD50 of A/Taiwan/1/86 (H1N1) virus.
Splenocytes were harvested three to four months later and
stimulated in vitro for five days with vaccinia-NP or vac-
cinia-gp120. After stimulation, ten million purified CD8+
T cells or CD8- cells isolated by AutoMacs were injected via
the tail vein into naïve Balb/c mice. Four hours later, they
were challenged by intranasal inoculation of 10 μl con-
taining 200 MID50 of A/HK/68 virus (without anesthesia).
Virus titers in the nasal passages and lungs were assessedRespiratory Research 2007, 8:44 http://respiratory-research.com/content/8/1/44
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Characteristics of purified T cells Figure 1
Characteristics of purified T cells. The frequency of CD8+ and CD4+ T cells before (top) and after (bottom) separation using 
AutoMacs are presented. Effector CTLs were labeled with magnetic CD8a (Lyt-2) MicroBeads and CD8+ and CD8- cells col-
lected by passage through a magnetized column. The cells were stained with CD8-PE and CD4-FITC conjugated monoclonal 
antibodies, respectively. Forward (FS) and side scatter (SC) plots of total lymphocytes (left), two-parameter histogram of gated 
CD8-PE+/CD4-FITC+ cells (middle) and prism display of cell frequencies are shown for un-separated CTL (top) and purified 
CD8+ CTLs (bottom) are shown a representative sample.
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Table 1: Specificity of purified CD8+ CTL a
% specific lysis b
Stimulation Cell Fraction % CD8+ cells % CD4+ cells A/HK/68 Vac-NP Vac-gp120 B/Panama
Vac-NP CD8+ 97.3 1.1 22.4 44.3 1.3 0.0
CD8- 0.6 75.5 NT 1.1 NT 2.7
Vac-gp120 CD8+ 90.1 0.0 0.34 0.0 9.02 NT
CD8- 0.0 74.2 NT 3.3 NT NT
a Splenocytes from Balb/c mice primed with influenza A/Taiwan (H1N1) virus were stimulated with 2 pfu/cell of recombinant Vac-NP or vaccinia-
gp120 for 5 days. CD8+ T cells were obtained by positive selection using AutoMacs instrument. The percentage of CD8+ and CD4+ T cells 
determined by dual color flow cytometry and % lysis in purified CD8+ and CD8- fractions are presented. b Lysis of P815 (H-2d) target cells with the 
indicated infection was determined in the 4-hour chromium release assay. Percent specific lysis at 40:1 E:T ratio is shown. NT = not tested.Respiratory Research 2007, 8:44 http://respiratory-research.com/content/8/1/44
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on day 8. This time period permits assessment of virus
clearance because CD8+ T cells do not prevent virus infec-
tion and differences may not be detected early after infec-
tion [26]. In normal mice, influenza virus replication
peaks at three for four days and cleared by approximately
twelve days [26,18,20]. Figure 2 shows that transfer of
CD8+ T cells stimulated in vitro with vaccinia-NP induced
a significant reduction of virus replication in both lung,
nasal turbinate and nasal passages (p < 0.001–0001)
when compared to CD8- cells from vaccinia-NP stimu-
lated cultures. CD8+ T cells from vaccinia-gp120 stimu-
lated cultures did not reduce virus titers. Thus, influenza
NP-specific CD8+  CTL from influenza infected mice
reduced lung and nasal virus replication following chal-
lenge with influenza A virus of a different subtype.
ii) T cells from plasmid NP DNA vaccinated mice
NP DNA immunization of mice prevented mortality after
challenge with virulent influenza viruses (data not
shown). Thus, NP DNA immunized mice that survived
influenza A virus challenge should contain high numbers
of NP-specific CD8+ T cells. To further determine whether
NP-specific CD8+ CTL play a role in the control of influ-
enza virus in the upper respiratory mucosa, NP-specific
CD8+ CTL from the NP DNA immunized mice that sur-
vived an A/Hong Kong/68 virus challenge were expanded
in vitro three months later and used for adoptive transfer
studies. Splenocytes were harvested and stimulated with
vaccinia recombinants encoding influenza NP, HIV gp120
(negative control) or with influenza A/HK/68 (H3N2)
virus for 5 days; a negative control consisted of un-stimu-
lated splenocytes from un-immunized mice. Induced
effector cells were enriched for CD8+ CTL by MACS or
AutoMacs. Ten million CD8+ T cells were injected intra-
peritoneally into naive Balb/c mice; 4 hours later they
were challenged intranasally with a small volume of
saline (10 μl) containing 100 MID50 of an influenza A/
HK/68 (H3N2) virus under light Metofane anesthesia.
Virus quantities in nasal passages and lungs were assessed
8 days later. [The small inoculum IN challenge was used
to ensure that virus was deposited primarily in the nose
[30].] Adoptive transfer of CD8+ CTL from cultures stimu-
lated with Vac-NP or live influenza A/HK/68 resulted in
significant reduction in lung (Figure 3, left panel) and
nasal wash (Figure 3, right panel) virus titers when com-
pared to mice given unstimulated unimmunized or Vac-
gp120-stimulated CD8+ T cells. These results showed that
CD8+ T cells generated from the NP DNA-vaccinated mice
that survived influenza A virus challenge could reduce
virus shedding at the upper respiratory mucosal surface.
Discussion
The present study was initiated to determine whether
CD8+ T cells alone can control an influenza virus infection
in the epithelial cells lining the respiratory tract because
human influenza virus infection is primarily a mucosal
infection with a significant involvement of the upper res-
piratory tract. In previous reported studies, adoptive trans-
fer of unfractionated influenza immune T cells or cloned
influenza-specific CD8+ T cells [4,31,1], resulted in signif-
icant clearance of influenza virus from the lungs and pro-
tection against pneumonia-induced death among the
recipient mice. Although, depletion of T cell subsets in vivo
suggested that CD8+ T cells were required for clearance of
the lung influenza virus infection [5,6], CD8+ deficient
mice results were inconsistent [32,33,7]. This was due
possibly to unpredictable compensatory mechanisms in
these gene knock out animals [34-36]. Although above
studies demonstrated or suggested a role for CD8+ cells in
the mouse pneumonia model of influenza, they did not
evaluate whether they functioned in clearance of influ-
enza virus from the respiratory mucosa.
In the present study, highly purified NP-specific CD8+
CTL, were shown to mediate clearance of influenza infec-
tion from both the lung and nasal mucosa of influenza-
infected mice. The NP-specific CD8+ CTL were generated
from mice immunized with plasmid NP DNA vaccine that
survived influenza A virus challenge and from mice
immunized with live influenza virus infection by stimula-
tion in vitro with a vaccinia-NP vector. Control CD8+ T
cells stimulated with vaccinia-gp120 did not kill influenza
virus-infected target cells in vitro and did not mediate
clearance of virus in vivo. In addition CD8- cells (includ-
ing CD4+ T cells, B cells and macrophages) did not medi-
Protective effects of CD8+ CTLs from influenza-infected mice Figure 2
Protective effects of CD8+ CTLs from influenza-infected 
mice. Splenic lymphocytes from Balb/c mice surviving A/Tai-
wan (H1N1) infection were stimulated with vaccinia-NP and 
vaccinia-gp120, respectively, for 5 days. CD8+ and CD8- cells 
(CD4+ T cells, B cells and macrophages) were obtained using 
AutoMacs. 1 × 107 cells were injected into the tail vein of the 
mice (6 per group). Four hours later, they were challenged 
by intranasal inoculation of 200 MID50 of influenza A/HK68 
virus. Virus in the lung, nasal turbinate and nasal wash was 
measured 8 days later. * P < 0.005. Values are GMT log10/ml 
of lung or nasal turbinate homogenate ± SEM.
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ate clearance of virus. Thus, the present adoptive transfer
experiments demonstrate that NP-induced CD8+ CTL can
promote clearance of influenza virus infection in epithe-
lial cells lining the respiratory tract. Moreover, we found
no evidence for a direct role for CD4+ T cells in viral clear-
ance although they may be important in supporting the
development of CD8+ effector T cells [37,38,6]. Data from
some laboratories have indicated that CD4+ T cells are not
required either for the induction or function of CD8+ CTL
[37] while other studies suggest otherwise [38,6].
Two studies concluded that NP specific T cells do not
exhibit antiviral activity in vivo [39,32]. In one study, mice
immunized with influenza NP-vaccinia and challenged
with heterotypic influenza A virus had significantly
reduced lung virus titers when the mice were challenged 9
and 30 days following immunization but the authors con-
cluded that NP-induced CTLs did not protect against
influenza virus challenge [32]. In the second study, mice
were immunized with vaccinia constructs expressing
NP147–155 epitopic peptide and then challenged 9 days
later with a lethal dose of heterotypic influenza A virus
[39]. These NP peptide vaccinia constructs failed to reduce
lung virus titers and mortality but the CTLs were directed
to a single NP epitope and were probably inadequate to
protect against a lethal influenza challenge.
The role of contact-mediated T cell cytotoxicity against
cytopathic viruses such as influenza remains controver-
sial. Some studies have suggested that cytokines released
by T cells and neutralizing antibodies constitute the pri-
mary protective mechanisms [9]. In a study by Doherty's
group, it was shown that mice primed with influenza A/
H1N1 virus clear an A/H3N2 influenza challenge 2–3
days earlier than naïve mice [40]. It was further shown
that virus-specific CD8+ T cells produce IFN-γ within six
hours while it takes 4–5 days for CD8+ T cells to accumu-
late in the infected local mucosal epithelium [40]. In
those studies, the kinetics of reduction in lung virus titer
preceded the accumulation of virus-specific NP366–
474tetramer+ CD8+ T cells, but reductions partially over-
lapped peak accumulation of the CD8+ T cells. Other stud-
ies using perforin and Fas deficient chimeric mice (P-/-/
Fas-/-) showed that CD8+ CTL could clear influenza virus
infection via a perforin-dependent pathway and, in the
absence of perforin, via virus-infected lung cells express-
ing Fas [41]. These results are indicative of a contact-
dependent mechanism requiring perforin and/or Fas. The
results presented here represent a direct demonstration
that CD8+ T cells constitute an effective mechanism for
clearance of influenza virus infection in the upper respira-
tory mucosa. Thus, the suggestion that antigen-specific
CTLs cannot cross the basement membrane to function
effectively on infected epithelial cells does not appear to
be true [9].
Conclusion
These results support an effector role for CD8+ CTL activity
in the results of McMichael and coworkers who showed
an inverse correlation between influenza virus shedding
from the nose and the level of HLA-restricted CD8+ CTL
activity in the blood of human volunteers challenged with
an influenza virus [10]. In this regard, it is important to
emphasize that the function of CD8+ CTL is not to prevent
viral infection but rather to mediate clearance of an infec-
tion and, thereby, promote recovery from disease and a
reduction in disease severity [42]. Currently available data
indicate that prevention of influenza infection requires
induction of antibody to the surface viral hemagglutinin
(HA) or the NA in both serum and respiratory secretions
[43]. An obvious implication of the present findings is
that NP-specific CD8+ CTL activity can augment protec-
tion against influenza induced by antibody and is a desir-
able immune response for influenza vaccines.
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